Clinical trials: Localized Prostate Cancer
Prostate Cancer
Radiation Therapy in Treating Patients With Stage II Prostate Cancer
RATIONALE: Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue.
- Trial name
- NCT00033631
- Testing
- 70.2 Gy 3D-CRT/IMRT, 79.2 Gy 3D-CRT/IMRT
- Where
- 86 sites in United States, Canada
- Volunteers
- 1,534 people
- Sponsor
- Radiation Therapy Oncology Group
Prostate Cancer
Comparison of Radiation Therapy Regimens in Treating Patients With Localized Prostate Cancer
RATIONALE: Radiation therapy uses high-energy x-rays to damage tumor cells. It is not yet known which regimen of radiation therapy is more effective for prostate cancer.
- Trial name
- NCT00010244
- Testing
- radiation therapy
- Where
- 19 sites in France
- Volunteers
- 306 people
- Sponsor
- UNICANCER
Prostate Cancer
TRUEBEAM Stereotactic Body Radiotherapy for Localized Prostate Cancer
The purpose of this study is to determine the effects of TrueBeam stereotactic body radiosurgery in patients with prostate cancer.
- Trial name
- NCT04552509
- Testing
- Stereotactic Body Radiotherapy
- Where
- United States
- Volunteers
- 167 people
- Sponsor
- Linda Chan, MD
Prostate Cancer
Study of Enzalutamide (Formerly MDV3100) as a Neoadjuvant Therapy for Patients Undergoing Prostatectomy for Localized Prostate Cancer
The purpose of this study is to determine if enzalutamide is an effective therapy in treating localized prostate cancer prior to prostatectomy.
- Trial name
- NCT01547299
- Testing
- Enzalutamide, Leuprolide, Dutasteride
- Where
- 4 sites in United States, Canada
- Volunteers
- 52 people
- Sponsor
- Pfizer
Prostate Cancer
Pilot Study to Investigate Magnetic Resonance (MR) Image Guided Focal Therapy in Prostate Cancer
Background: The ability to treat early prostate cancer is still limited. Thermal ablation methods are being tested for focal prostate cancer therapy. Researchers want to improve on these methods.
- Trial name
- NCT04808427
- Testing
- TULSA-PRO
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Cancer
Study of Focal Ablation of the Prostate With NanoTherm® Therapy System for Intermediate-Risk Prostate Cancer
Stage 2B: NanoTherm ablation of focal prostate cancer in small lesions in Gleason 3+4 disease. The outcome of this ablation is validated by a transperineal biopsy at 4 months after ablation.
- Trial name
- NCT05010759
- Testing
- NanoTherm Ablation
- Where
- 4 sites in United States
- Volunteers
- 3 people
- Sponsor
- MagForce USA
Carcinoma Prostate
Combined LDR Boost and HDR Whole Gland
This is a dose finding Phase I/II study of combined focused LDR brachytherapy boost with whole gland single fraction HDR for men with low and intermediate risk prostate cancer and Dominant Intraprostatic Lesion (DIL) visible on…
- Trial name
- Delight (NCT03323879)
- Testing
- LDR/HDR
- Where
- Canada
- Volunteers
- 7 people
- Sponsor
- Sunnybrook Health Sciences Centre
Neoplasms, Breast Neoplasms
Rehabilitation of Cancer Survivors in Denmark: The Effect of a Psychosocial Rehabilitation Course
This randomized study evaluates the effect of a multi-focused, psychosocial 6-day residential rehabilitation course at a Danish rehabilitation centre for cancer survivors.
- Conditions
- Neoplasms, Breast Neoplasms, Colorectal Neoplasms, Prostatic Neoplasms
- Trial name
- NCT01086683
- Testing
- Psychosocial rehabilitation course
- Where
- Denmark
- Volunteers
- 513 people
- Sponsor
- Danish Cancer Society
Bone Cancer, Bone Metastases
Study Comparing the Safety and Effectiveness of Magnetic Resonance Guided Focused Ultrasound (MRgFUS) and External Beam Radiation (EBRT) for Treatment of Metastatic Bone Tumors and Multiple Myeloma
The goal of this study is to collect comparative data on safety and efficacy of MR Guided Focused Ultrasound and External Beam Radiation for treatment of metastatic bone tumors or multiple myeloma.
- Conditions
- Bone Cancer, Bone Metastases, Pain
- Trial name
- NCT01091883
- Testing
- Exablate treatment, Radiation
- Where
- Taiwan
- Volunteers
- 60 people
- Sponsor
- InSightec
Breast Cancer, Ovarian Cancer
OPTimizing Treatment Focused Genetic Testing IN Cancer
This two-part randomized controlled trial aims to evaluate the impact of pre-test video education as compared to pre-test Chatbot education.
- Conditions
- Breast Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer
- Trial name
- OPT-IN (NCT04066361)
- Testing
- Chatbot, Video Education
- Where
- United States
- Volunteers
- 301 people
- Sponsor
- Dana-Farber Cancer Institute
Primary Malignant Neoplasm of Prostate (Diagnosis)
MRI-Guided Cryoablation for Focal Native Prostate Cancer
The purpose of this research is to collect data about the MRI cryoablation procedure your doctor(s) would normally perform in order to treat the participants focal prostate cancer and to evaluate the participants condition after…
- Trial name
- NCT04797039
- Testing
- MR guided cryoablation
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- Mayo Clinic
Lung Cancer, Breast Cancer
Telemedicine-mHealth Symptom Cluster Intervention for Advanced Cancer Patients: Finding Our Center Under Stress (FOCUS)
This clinical trial studies whether a telemedicine-mobile health (mHealth) intervention, Finding Our Center Under Stress (FOCUS), improves symptom management in patients with cancer that may have spread from where it first…
- Conditions
- Lung Cancer, Breast Cancer, Prostate Cancer, Multiple Myeloma
- Trial name
- FOCUS (NCT07102212)
- Testing
- mHealth Intervention
- Where
- United States
- Volunteers
- 120 people
- Sponsor
- Ohio State University Comprehensive Cancer Center
Cancer
Early Intervention vs. Standard Palliative Care in Improving End-of-Life Care in Advanced Cancer Patients
RATIONALE: Palliative care may help patients with advanced cancer live more comfortably. PURPOSE: This randomized clinical trial is studying an early intervention palliative care program to see how well it works compared to a…
- Trial name
- NCT00253383
- Testing
- counseling intervention, educational intervention, psychosocial assessment and care
- Where
- 2 sites in United States
- Volunteers
- 329 people
- Sponsor
- Dartmouth-Hitchcock Medical Center
Prostate Cancer
Focal Prostate Radio-Frequency Ablation
The main purpose of this study is to evaluate the safety and efficacy of focal (targeted) Radio-Frequency Ablation (RFA) in men with low or intermediate-risk, clinically localized prostate cancer.
- Trial name
- NCT02328807
- Testing
- Radio-Frequency Ablation (RFA)
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Prostate Cancer, Prostate Adenoma
Efficacy and Safety of Radical Prostatectomy (RP) With or Without Salvage Radiotherapy Versus RP With Extended Pelvic Lymph Node Dissection for Localized Intermediate- and High-risk Prostate Cancer With a Briganti Nomogram≥7%
The goal of this clinical trial is to evaluate efficacy and safety of radical prostatectomy (RP) with or without salvage radiotherapy versus RP with extended pelvic lymph node dissection (ePLND) in males who have localized…
- Trial name
- PRESEL (NCT07115992)
- Testing
- RARP±SRT, RARP+ePLND
- Where
- China
- Volunteers
- 270 people
- Sponsor
- Ruijin Hospital
Prostate Cancer
Study in Predicting Outcome of Patients Undergoing Radiation Therapy for Prostate Cancer
RATIONALE: Proteins found in blood and urine samples may help predict outcome and allow doctors to plan more effective treatment.
- Trial name
- NCT00045331
- Testing
- proteomic profiling
- Where
- 2 sites in United States
- Sponsor
- National Cancer Institute (NCI)
Localised Prostate Cancer
Microwave Intervention Under Local Anesthesia
This study aims to evaluate the feasibility of performing a focal Targeted Microwave Ablation (TMA) procedure using Koelis TMA® under local anesthesia in patient with localized prostate cancer.
- Trial name
- MILA (NCT07412275)
- Testing
- Local Anesthesia (lidocaine hydrochloride)
- Where
- 2 sites in Belgium, France
- Volunteers
- 20 people
- Sponsor
- Koelis
PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten
Pomegranate-Extract Pill in Preventing Tumor Growth in Patients With Localized Prostate Cancer Undergoing Active Surveillance
This randomized phase II trial studies pomegranate-extract pill in preventing tumor growth in patients with prostate cancer that is limited to a certain part of the body (localized), who have chosen observation as their treatment…
- Conditions
- PSA Level Less Than or Equal to Fifteen, PSA Level Less Than Ten, Stage I Prostate Cancer AJCC v7, Stage II Prostate Cancer AJCC v7
- Trial name
- NCT02095145
- Testing
- Laboratory Biomarker Analysis, Pharmacological Study, Pomegranate-Extract Pill
- Where
- 4 sites in United States
- Volunteers
- 38 people
- Sponsor
- National Cancer Institute (NCI)
Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8
High Dose-Rate Brachytherapy and Stereotactic Body Radiotherapy for the Treatment of Prostate Adenocarcinoma
This phase II trial investigates the effect of high dose-rate brachytherapy and stereotactic body radiotherapy in treating patients with prostate adenocarcinoma.
- Conditions
- Prostate Adenocarcinoma, Stage IIB Prostate Cancer American Joint Committee on Cancer (AJCC) v8, Stage IIC Prostate Cancer AJCC v8, Stage III Prostate Cancer AJCC v8
- Trial name
- HYDRA (NCT04945642)
- Testing
- High-Dose Rate Brachytherapy, Stereotactic Body Radiation Therapy
- Where
- United States
- Volunteers
- 52 people
- Sponsor
- Jonsson Comprehensive Cancer Center
Adenocarcinoma of the Prostate
First in Man Clinical Study to Evaluate Safety and Tolerability of an Oncolytic Adenovirus in Prostate Cancer Patients.
This open label, dose escalating study is a phase I/IIa first in man study designed to evaluate the safety and tolerability of intratumoral administration of a novel oncolytic adenovirus (ORCA-010) in treating diagnosed treatment…
- Trial name
- NCT04097002
- Testing
- ORCA-010
- Where
- 5 sites in Canada
- Volunteers
- 24 people
- Sponsor
- Orca Therapeutics B.V.